3-V Biosciences doses first patient with fatty acid inhibitor for NASH

3-V Biosciences dosed its first patient in a phase 2 clinical trial of a fatty acid inhibitor candidate from Ascletis for the treatment of nonalcoholic steatohepatitis, according to a press release.
“Lipid synthesis is an important driver of NASH,” Rohit Loomba, MD, from the University of California San Diego, and coordinating investigator of the phase 2 study, said in the release. “The imaging techniques in this study will give us a very clear understanding of the impact this drug has on liver fat, a key driver of this disease.”
TVB-2640 is an orally bioavailable

Source link

Related posts

Peer-Led Education Helps Physicians Save Time With EHRs


ΦCrAss001 represents the most abundant bacteriophage family in the human gut and infects Bacteroides intestinalis


May 2018 Briefing – Gastroenterology


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy